Ashland Inc. Reports $12 Million Net Loss, Significant Improvement from Last Year

Ashland Inc. reported a net loss of $12 million, or $(0.30) per diluted share, for the three months ended December 31, 2025, a significant improvement compared to a net loss of $165 million, or $(3.51) per diluted share, in the same period last year. The company attributed this positive shift to a combination of factors, including a federal tax refund of $103 million and a reduction in operating losses, which fell to $6 million from $179 million year-over-year. Total sales for the quarter were $386 million, down from $405 million in the prior year, primarily due to lower sales volume and unfavorable pricing, partially offset by favorable foreign currency exchange rates.

In terms of operational performance, Ashland's reportable segments showed mixed results. The Life Sciences segment saw a slight increase in sales to $139 million from $134 million, while Personal Care and Specialty Additives experienced declines, with sales of $123 million and $102 million, respectively. The Intermediates segment reported sales of $31 million, down from $33 million. The overall operating loss for the company was reduced significantly, reflecting improved cost management and operational efficiencies, particularly in the Life Sciences and Personal Care segments.

Strategically, Ashland has been active in restructuring and optimizing its operations. The company initiated a $30 million pre-tax restructuring plan aimed at offsetting impacts from recent divestitures, including the sale of its Avoca business. This plan is expected to yield approximately $50 million to $55 million in pre-tax savings as market conditions improve. Additionally, Ashland has been advancing a multi-year manufacturing network optimization program, which is anticipated to enhance operational cost efficiency and strengthen its competitive position.

On the operational front, Ashland's cash flow from continuing operations was $125 million for the quarter, a notable turnaround from an outflow of $30 million in the prior year. The company ended the period with cash and cash equivalents of $304 million, up from $215 million at the end of the previous quarter. Ashland's total debt remained stable at $1.387 billion, with a debt-to-capital ratio of 42%. The company continues to maintain a strong liquidity position, with $900 million available from cash and credit facilities.

Looking ahead, Ashland has narrowed its full-year fiscal 2026 Adjusted EBITDA guidance to a range of $400 million to $420 million, reflecting temporary impacts from operational disruptions. The company remains optimistic about its core markets in Personal Care and Life Sciences, which are expected to show resilience. Ashland's ongoing cost-saving initiatives and operational improvements are anticipated to support its performance in the upcoming quarters, with expectations for stronger results in the second half of the fiscal year.